Cantor Fitzgerald Expects Stronger Earnings for aTyr Pharma

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for aTyr Pharma to ($0.64), an improvement from the previous estimate of ($0.66), while maintaining a "Neutral" rating on the stock.
• Several research firms have downgraded aTyr Pharma, with Jones Trading and HC Wainwright both reducing ratings to "hold" as of Monday, and Wall Street Zen downgrading to "sell" earlier in August.
• The stock opened at $1.03 on Thursday, with a market capitalization of approximately $100.44 million, while institutional investors own about 61.72% of the company’s shares.

aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for aTyr Pharma in a report issued on Tuesday, September 16th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the company will post earnings per share of ($0.64) for the year, up from their previous forecast of ($0.66). Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for aTyr Pharma's current full-year earnings is ($0.91) per share. Cantor Fitzgerald also issued estimates for aTyr Pharma's FY2026 earnings at ($0.39) EPS.

Several other research firms have also recently weighed in on ATYR. Jones Trading cut aTyr Pharma from a "strong-buy" rating to a "hold" rating in a report on Monday. HC Wainwright cut aTyr Pharma from a "buy" rating to a "neutral" rating in a report on Monday. Wall Street Zen cut aTyr Pharma from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Jefferies Financial Group increased their price target on aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Finally, Leerink Partners reissued a "market perform" rating on shares of aTyr Pharma in a report on Monday. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, aTyr Pharma presently has a consensus rating of "Hold" and a consensus price target of $23.25.

aTyr Pharma Price Performance

NASDAQ ATYR opened at $1.03 on Thursday. The business's fifty day moving average price is $5.11 and its 200-day moving average price is $4.32. The stock has a market capitalization of $100.44 million, a price-to-earnings ratio of -1.28 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. aTyr Pharma has a 1-year low of $0.97 and a 1-year high of $7.29.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04).

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Oxford Asset Management LLP purchased a new position in shares of aTyr Pharma during the second quarter valued at about $70,000. Octagon Capital Advisors LP grew its position in shares of aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock valued at $19,367,000 after purchasing an additional 268,000 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of aTyr Pharma during the second quarter valued at about $99,000. California State Teachers Retirement System purchased a new position in shares of aTyr Pharma during the second quarter valued at about $28,000. Finally, Raymond James Financial Inc. grew its position in shares of aTyr Pharma by 79.3% during the second quarter. Raymond James Financial Inc. now owns 24,839 shares of the company's stock valued at $126,000 after purchasing an additional 10,989 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.